Shiloh
Editor, Senior Moderator
Source: http://www.cidrap.umn.edu/news-perspective/2019/08/stewardship-resistance-scan-aug-16-2019
Stewardship / Resistance Scan for Aug 16, 2019
Funding for Staph vaccine; Delafloxacin-resistant MRSA
Filed Under:
Antimicrobial Stewardship; MRSA
[h=3]New CARB-X funding announced for Staphylococcus vaccine candidate[/h] CARB-X yesterday announced additional funding to expand development of a vaccine against Staphylococcus aureus.
The award of $1.6 million will allow Integrated Biotherapeutics (IBT) of Rockville, Maryland, to expand research and development efforts for IBT-V02, a multivalent vaccine for the prevention of S aureus infections, including those caused by methicillin-resistant S aureus (MRSA). With the additional funding, IBT will evaluate the efficacy of the vaccine against strains of S aureus circulating in developing nations, and explore development of a freeze-dried version for use in regions where cold storage systems aren't available.
"Effective vaccines can prevent life-threatening bacterial infections and help reduce overuse and misuse of antibiotics, which is a particular problem in many developing nations and a threat to global health security as it fuels the spread of antibiotic resistance," M. Javad Aman, PhD, IBT president and chief science officer, said in a CARB-X press release.
CARB-X (the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) awarded IBT up to $8.5 million in 2017 to complete pre-clinical studies and a phase 1 clinical trial for IBT-V02. The additional support comes from two CARB-X partners?the UK government's Global Antimicrobial Resistance Innovation Fund and the Bill & Melinda Gates Foundation?that have earmarked funds specifically for development of antibacterial approaches that can be used in low- and middle-income countries.
Aug 15 CARB-X press release
[h=3]Brooklyn study describes emerging delafloxin resistance in MRSA[/h] More than 20% of MRSA isolates collected from seven hospitals in Brooklyn were resistant to delafloxacin, researchers reported yesterday in Clinical Infectious Diseases.
During a surveillance study conducted by researchers from the State University of New York (SUNY)-Downstate Medical Center in 2017, 757 unique patient isolates of S aureus were collected. Among the MRSA isolates, 60 (22%) were non-susceptible to delafloxicin.
Sequence typing of 16 delafloxacin-resistant representatives from each of the seven hospitals showed that 15 were MRSA, and 14 of these belonged to sequence type (ST)105, a healthcare-associated MRSA strain, along with one methicillin-susceptible isolate. The other MRSA isolate belonged to ST8, a community-associated strain. Whole-genome sequencing of six of the isolates found multiple mutations involving gyrase and topoisomerase IV genes, which are targeted by delafloxacin.
Clinical data on seven patients with delafloxacin-resistant isolates showed that all had extensive contact with the healthcare system and multiple medical problems, and five had previously been on fluoroquinolones.
The researchers note that the isolates were collected in early 2017, prior to the Food and Drug Administration (FDA) approval and availability of delafloxacin. The FDA approved the drug for treatment of acute bacterial skin and skin-structure infections.
Aug 15 Clin Infect Dis abstract
Stewardship / Resistance Scan for Aug 16, 2019
Funding for Staph vaccine; Delafloxacin-resistant MRSA
Filed Under:
Antimicrobial Stewardship; MRSA
[h=3]New CARB-X funding announced for Staphylococcus vaccine candidate[/h] CARB-X yesterday announced additional funding to expand development of a vaccine against Staphylococcus aureus.
The award of $1.6 million will allow Integrated Biotherapeutics (IBT) of Rockville, Maryland, to expand research and development efforts for IBT-V02, a multivalent vaccine for the prevention of S aureus infections, including those caused by methicillin-resistant S aureus (MRSA). With the additional funding, IBT will evaluate the efficacy of the vaccine against strains of S aureus circulating in developing nations, and explore development of a freeze-dried version for use in regions where cold storage systems aren't available.
"Effective vaccines can prevent life-threatening bacterial infections and help reduce overuse and misuse of antibiotics, which is a particular problem in many developing nations and a threat to global health security as it fuels the spread of antibiotic resistance," M. Javad Aman, PhD, IBT president and chief science officer, said in a CARB-X press release.
CARB-X (the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) awarded IBT up to $8.5 million in 2017 to complete pre-clinical studies and a phase 1 clinical trial for IBT-V02. The additional support comes from two CARB-X partners?the UK government's Global Antimicrobial Resistance Innovation Fund and the Bill & Melinda Gates Foundation?that have earmarked funds specifically for development of antibacterial approaches that can be used in low- and middle-income countries.
Aug 15 CARB-X press release
[h=3]Brooklyn study describes emerging delafloxin resistance in MRSA[/h] More than 20% of MRSA isolates collected from seven hospitals in Brooklyn were resistant to delafloxacin, researchers reported yesterday in Clinical Infectious Diseases.
During a surveillance study conducted by researchers from the State University of New York (SUNY)-Downstate Medical Center in 2017, 757 unique patient isolates of S aureus were collected. Among the MRSA isolates, 60 (22%) were non-susceptible to delafloxicin.
Sequence typing of 16 delafloxacin-resistant representatives from each of the seven hospitals showed that 15 were MRSA, and 14 of these belonged to sequence type (ST)105, a healthcare-associated MRSA strain, along with one methicillin-susceptible isolate. The other MRSA isolate belonged to ST8, a community-associated strain. Whole-genome sequencing of six of the isolates found multiple mutations involving gyrase and topoisomerase IV genes, which are targeted by delafloxacin.
Clinical data on seven patients with delafloxacin-resistant isolates showed that all had extensive contact with the healthcare system and multiple medical problems, and five had previously been on fluoroquinolones.
The researchers note that the isolates were collected in early 2017, prior to the Food and Drug Administration (FDA) approval and availability of delafloxacin. The FDA approved the drug for treatment of acute bacterial skin and skin-structure infections.
Aug 15 Clin Infect Dis abstract